ATE214942T1 - Fibrinogen-bildungsprotein - Google Patents

Fibrinogen-bildungsprotein

Info

Publication number
ATE214942T1
ATE214942T1 AT93921159T AT93921159T ATE214942T1 AT E214942 T1 ATE214942 T1 AT E214942T1 AT 93921159 T AT93921159 T AT 93921159T AT 93921159 T AT93921159 T AT 93921159T AT E214942 T1 ATE214942 T1 AT E214942T1
Authority
AT
Austria
Prior art keywords
formation protein
protein
fragment
fibrinogen formation
fibrinogen
Prior art date
Application number
AT93921159T
Other languages
English (en)
Inventor
Maria K Boden
Jan-Ingmar Flock
Original Assignee
Alfa Laval Agri Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9202720A external-priority patent/SE9202720D0/xx
Priority claimed from SE9302955A external-priority patent/SE9302955D0/xx
Application filed by Alfa Laval Agri Internat Ab filed Critical Alfa Laval Agri Internat Ab
Application granted granted Critical
Publication of ATE214942T1 publication Critical patent/ATE214942T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93921159T 1992-09-21 1993-09-20 Fibrinogen-bildungsprotein ATE214942T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9202720A SE9202720D0 (sv) 1992-09-21 1992-09-21 Fibrinogen binding protein
SE9302955A SE9302955D0 (sv) 1993-09-13 1993-09-13 A fibrinogen binding protein
PCT/SE1993/000759 WO1994006830A1 (en) 1992-09-21 1993-09-20 Fibrinogen binding protein

Publications (1)

Publication Number Publication Date
ATE214942T1 true ATE214942T1 (de) 2002-04-15

Family

ID=26661530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921159T ATE214942T1 (de) 1992-09-21 1993-09-20 Fibrinogen-bildungsprotein

Country Status (7)

Country Link
US (1) US6299879B1 (de)
EP (1) EP0621875B1 (de)
AT (1) ATE214942T1 (de)
AU (1) AU4837193A (de)
CA (1) CA2124210A1 (de)
DE (1) DE69331758T2 (de)
WO (1) WO1994006830A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
EP0771351A1 (de) * 1994-06-07 1997-05-07 The Rockefeller University Oberflächenprotein aus staphylococcus aureus
SE9402490D0 (sv) * 1994-07-15 1994-07-15 Jan Ingmar Flock Vitronection binding protein
GB9521146D0 (en) * 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
JPH11514870A (ja) * 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
US5858709A (en) * 1996-10-15 1999-01-12 Smithkline Beecham P.L.C. Fibronectin binding protein B compounds
JPH11505130A (ja) * 1995-10-16 1999-05-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な細胞表面タンパク質化合物
US6013482A (en) 1996-10-15 2000-01-11 Smithkline Beecham Plc Cell surface protein compounds
SE9602496D0 (sv) * 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US5882871A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US6107071A (en) 1996-09-24 2000-08-22 Smithkline Beecham Corporation Histidinol dehydrogenase
EP1034277B1 (de) * 1997-11-26 2012-06-27 Inhibitex, Inc. Extrazelluläre Matrix-bindende Proteine von Staphylococcus aureus
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US20030105020A1 (en) * 2001-11-16 2003-06-05 Jan-Ingmar Flock Use of a composition
WO2003041726A1 (en) * 2001-11-16 2003-05-22 Biostapro Ab Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug
WO2004094600A2 (en) * 2003-04-16 2004-11-04 The Texas A & M University System Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation
WO2005005630A2 (en) 2003-07-08 2005-01-20 Umc Utrecht Holding B.V. Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases
JP2010524454A (ja) 2007-04-19 2010-07-22 モレキュラー ディテクション インコーポレーテッド 抗生物質耐性細菌の検出および分析のための方法、組成物、およびキット
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
AU2008292897B2 (en) * 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
PT3281947T (pt) 2009-04-03 2020-05-07 Univ Chicago Composições e métodos relacionados com variantes da proteína a (spa)
EP2588120B1 (de) 2010-07-02 2017-11-15 The University of Chicago Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
CN101987866B (zh) * 2010-10-25 2013-01-23 中国人民解放军军事医学科学院基础医学研究所 金黄色葡萄球菌Efb蛋白C端抗原表位及其制备方法和用途
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP6556758B2 (ja) * 2014-01-24 2019-08-07 チャーチ、ウィリアム、アール． 黄色ブドウ球菌特異的抗体、それを用いた治療方法及び検出方法
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
BR112021022902A2 (pt) 2019-05-14 2022-01-25 Univ Chicago Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
SE454403B (sv) * 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel

Also Published As

Publication number Publication date
EP0621875B1 (de) 2002-03-27
CA2124210A1 (en) 1994-03-31
DE69331758T2 (de) 2002-11-14
AU4837193A (en) 1994-04-12
DE69331758D1 (de) 2002-05-02
WO1994006830A1 (en) 1994-03-31
US6299879B1 (en) 2001-10-09
EP0621875A1 (de) 1994-11-02

Similar Documents

Publication Publication Date Title
ATE214942T1 (de) Fibrinogen-bildungsprotein
DK0654078T3 (da) Thrombinblodfraktion til anvendelse i en medicinsk procedure
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
NO901399L (no) Aminosyrederivater.
DK1175909T3 (da) Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate
EP0643559A4 (de) Rezeptorbindende region des diphtherietoxius.
DE69532760D1 (de) Mittel zur verabreichung von antigenen
NO892407L (no) Aminosyrederivater.
AP9200410A0 (en) Retroviral protease inhibitors.
NO901033D0 (no) Aminosyrederivater.
DK0601154T3 (da) BPC-peptider, deres fremstilling og anvendelse
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
DK162421C (da) Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK675389A (da) Terapeutiske praeparater til forebyggelse af fibrinaflejringer
ES2092067T3 (es) Procedimiento de purificacion de una proteina altamente glicosilada.
DE3875859D1 (de) Zubereitungen zur verbesserung der adcc-therapien.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
DE69433745D1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
ES504996A0 (es) Un procedimiento para aislar un polipeptido purificado
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties